Medium cut-off membranes - closer to the natural kidney removal function

International Journal of Artificial Organs

Volumn 40, Issue 7, 2017, Pages 328-334

  Zweigart, Carina ^a   Boschetti de Fierro, Adriana ^a   Hulko, Michael ^a   Nilsson, Lars Göran ^b   Beck, Werner ^c   Storr, Markus ^a   Krause, Bernd ^a  

^a Research and Development   (Germany)

^b Medical Affairs   (Sweden)

^c Medical Affairs   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

REMOVAL FUNCTION;

ALBUMIN; IMMUNOGLOBULIN; UREMIC TOXIN;

ACUTE KIDNEY FAILURE; BLOOD FLOW VELOCITY; BLOOD PRESSURE; EDITORIAL; END STAGE RENAL DISEASE; HEMODIAFILTRATION; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYPOALBUMINEMIA; INFLAMMATION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOCYTE; ORGAN TRANSPLANTATION; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; ULTRAFILTRATION;

EID: 85021891438     PISSN: 03913988     EISSN: 17246040     Source Type: Journal    
DOI: 10.5301/ijao.5000603     Document Type: Editorial

References (55)

1. th International Congress of the InternationSociety for Hemodialysis: Global Challenges in HemodialysiHemodial Int. 2015;19(Suppl 2):S3-S73.
2. Kirsch AH, Lyko R, Nilsson L-G, et al. Performance of hemodalysis with novel medium cut-off dialyzers. Nephrol Dial Tranplant. 2016;32(1):165-172.
3. Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest. 2004;114(1):5-14.
4. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncom-municable diseases. Kidney Int. 2011;80(12):1258-1270.
5. Polyamide - The Evolution of a Synthetic Membrane for Renal Therapy. Contrib Nephrol. 1992;96:1-144.
6. Hakim RM, Fearon DT, Lazarus JM, Perzanowski CS. Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney Int. 1984;26(2):194-200.
7. Jacob AI, Gavellas G, Zarco R, Perez G, Bourgoignie JJ. Leukopenia, hypoxia, and complement function with different hemodialysis membranes. Kidney Int. 1980;18(4):505-509.
8. Franz HE. Dialyse 2001. Lengerich, Germany: Pabst Science Publishers 2002.
9. Krause B, Göhl H, Wiese F. Medizintechnik. In: K. Ohlrogge K, Ebert K, eds. Membranen: Grundlagen, Verfahren und in-dustrielle Anwendungen. Weinheim, Germany: Wiley-VCH 2006.
10. Reinhardt B, Krick G. Verfahrenstechnische Aspekte. In: Franz H E, Hörl W H, eds. Blutreinigungsverfahren: Technik und Klinik. Stuttgart-New York, Georg Thieme Verlag 1997.
11. Zaluska, WT, Ksiazek A, Roliski J. Effect of vitamin E modified cellulose membrane on human lymphocyte, monocyte, and granulocyte CD11b/CD18 adhesion molecule expression during hemodialysis. ASAIO J. 2001;47(6):619-22.
12. Gejyo F, Yamada T, Odani S, et al. A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun. 1985;129(3):701-706.
13. Stannat S, Bahlmann J, Kiessling D, Koch KM, Deicher H, Peter HH. Complement activation during hemodialysis. Comparison of polysulfone and cuprophan membranes. Contrib Nephrol. 1985;46:102-108.
14. Streicher E, Schneider H. The development of a polysulfone membrane. A new perspective in dialysis? Contrib Nephrol. 1985;46:1-13.
15. Schaefer RM, Heidland A, Hörl WH. Release of leukocyte elastase during hemodialysis. Effect of different dialysis membranes. Contrib Nephrol. 1985;46:109-117.
16. Locatelli F, Martin-Malo A, Hannedouche T, et al. Membrane Permeability Outcome (MPO) Study Group. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol. 2009;20(3):645-654.
17. Boschetti-de-Fierro A, Voigt M, Storr M, Krause B. Extended Characterization of a New Class of Dialysis Membranes: the High Cut-Off Membranes. Int J Artif Organs. 2013;36(7): 455-463.
18. Naka T, Haase M, Bellomo R. ‘Super High-Flux’ or ‘High Cut-Off’ Hemofiltration and Hemodialysis. In: Suzuki H, Hirasa-wa H, eds. Acute Blood Purification. Basel: S. Karger. 2010; 181-189.
19. Hutchison CA, Harding S, Mead G, et al. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs. 2008;32(12):910-917.
20. Fiedler R, Neugebauer F, Ulrich C, et al. Randomized controlled pilot study of 2 weeks treatment with high cutoff membrane for hemodialysis patients with elevated C-reactive protein. Artif Organs. 2012;36(10):886-893.
21. Gong D, Ji D, Zhang K, et al. Endotoxemia after high cutoff hemodialysis for treatment of patient with multiple myeloma can be prevented by using ultrapure dialysate: a case report. Hemodial Int. 2013;17(4):618-623.
22. Operator manual for the Baxter-Gambro HCO 1100 Instructions for use, N50 212 rev. 003-1.
23. Delanaye P, Lambermont B, Dogné JM, et al. Confirmation of high cytokine clearance by hemofiltration with a cellulose tri-acetate membrane with large pores: an in vivo study. Int J Artif Organs. 2006;29(10):944-948.
24. Tomo T, Matsuyama M, Nakata T, et al. Effect of high fiber density ratio polysulfone dialyzer on protein removal. Blood Purif. 2008;26(4):347-353.
25. Galli F, Benedetti S, Floridi A, et al. Glycoxidation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers. Kidney Int. 2005;67(2):750-759.
26. Kerr PG, Sutherland WH, de Jong S, Vaithalingham I, Williams SM, Walker RJ. The impact of standard high-flux polysulfone versus novel high-flux polysulfone dialysis membranes on inflammatory markers: a randomized, single-blinded, controlled clinical trial. Am J Kidney Dis. 2007;49(4): 533-539.
27. Ward RA. Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application? J Am Soc Nephrol. 2005;16(8):2421-2430.
28. Neirynck N, Vanholder R, Schepers E, Eloot S, Pletinck A, Glorieux G. An update on uremic toxins. Int Urol Nephrol. 2013;45(1):139-150.
29. Meert N, Waterloos MA, Van Landschoot M, et al. Prospective evaluation of the change of predialysis protein-bound uremic solute concentration with postdilution online hemodiafiltration. Artif Organs. 2010;34(7):580-585.
30. Duranton F, Cohen G, De Smet R, et al. European Uremic Toxin Work Group. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012;23(7):1258-1270.
31. Floege J, Granolleras C, Deschodt G, et al. High-flux synthetic versus cellulosic membranes for β 2-microglobulin removal during hemodialysis, hemodiafiltration and hemofiltration. Nephrol Dial Transplant. 1989;4(7):653-657.
32. Eloot S, Ledebo I, Ward RA. Extracorporeal removal of uremic toxins: can we still do better? Semin Nephrol. 2014;34(2): 209-227.
33. Lisowska-Myjak B. Uremic toxins and their effects on multiple organ systems. Nephron Clin Pract. 2014;128(3-4):303-311.
34. Tattersall JE, Ward RA. EUDIAL group. Online haemodiafiltration: definition, dose quantification and safety revisited. Nephrol Dial Transplant. 2013;28(3):542-550.
35. Ledebo I, Blankestijn PJ. Haemodiafiltration-optimal efficiency and safety. NDT Plus. 2010;3(1):8-16.
36. Chapdelaine I, de Roij van Zuijdweifn CLM, Mostovaya IM, et al. Optimization of the convection volume in online post-dilution haemodiafiltration: practical and technical issues. Clin Kidney J. 2015;8(2):191-198.
37. Meert N, Eloot S, Waterloos MA, et al. Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant. 2009;24(2): 562-570.
38. Tijink MS, Wester M, Glorieux G, et al. Mixed matrix hollow fiber membranes for removal of protein-bound toxins from human plasma. Biomaterials. 2013;34(32):7819-7828.
39. Meijers BK, Weber V, Bammens B, et al. Removal of the uremic retention solute p-cresol using fractionated plasma separation and adsorption. Artif Organs. 2008;32(3):214-219.
40. Brettschneider F, Tölle M, von der Giet M, et al. Removal of protein-bound, hydrophobic uremic toxins by a combined fractionated plasma separation and adsorption technique. Artif Organs. 2013;37(4):409-416.
41. Kaysen GA. Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol. 1998;9(12):2368-2376.
42. Krieter DH, Canaud B. High permeability of dialysis membranes: what is the limit of albumin loss? Nephrol Dial Transplant. 2003;18(4):651-654.
43. Caravaca F, Arrobas M, Dominguez C. Serum albumin and other serum protein fractions in stable patients on peritoneal dialysis. Perit Dial Int. 2000;20(6): 703-707.
44. Potier J, Queffeulou G, Bouet J. Are all dialyzers compatible with the convective volumes suggested for postdilution online hemodiafiltration? Int J Artif Organs. 2016;39(9):460-470.
45. Alp Ikizler T, Flakoll PJ, Parker RA, Hakim RM. Amino acid and albumin losses during hemodialysis. Kidney Int. 1994; 46(3):830-837.
46. Kaplan AA, Halley SE, Lapkin RA, Graeber CW. Dialysate protein losses with bleach processed polysulphone dialyzers. Kidney Int. 1995;47(2):573-578.
47. Le Roy FHM, Claeyssens S, Bertrand D, Freguia C, Godin M. Beta2-microglobulin removal and albumin losses in post-dilution hemodiafiltration: membrane effect [abstract]. Clin Kidney J. 2009;2(Suppl 2):ii1150.
48. Fournier A, Birmelé B, François M, Prat L, Halimi JM. Factors associated with albumin loss in post-dilution hemodiafiltration and nutritional consequences. Int J Artif Organs. 2015;38(2): 76-82.
49. Maduell F, Arias-Guillen M, Fontseré N, et al. Elimination of large uremic toxins by a dialyzer specifically designed for high-volume convective therapies. Blood Purif. 2014;37(2):125-130.
50. Tsuchida K, Minakuchi J. Albumin loss under the use of the high-performance membrane. Contrib Nephrol. 2011;173:76-83.
51. Santoro A, Mancini E. Cardiac effects of chronic inflammation in dialysis patients. Nephrol Dial Transplant. 2002;17(Suppl 8): 10-15.
52. Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3(5):1526-1533.
53. Locatelli F, Andrulli S, Pecchini F, et al. Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrol Dial Transplant. 2000;15(9):1399-1409.
54. Boschetti-de-Fierro A, Voigt M, Storr M, Krause B. MCO Membranes: Enhanced Selectivity in High-Flux Class. Sci Rep. 2015;5:18448.
55. Kirsch AH, Lechner P, Nilsson L-G, et al. Large middle-molecule removal during hemodialysis using a novel medium cutoff dialyzer. Nephrol Dial Transplant. 2016;31(Suppl 1):i230.